Cellectar Biosciences, Inc. 8-K

What Happened

• Cellectar Biosciences (CLRB) filed an 8-K reporting that on May 17, 2026 Dr. Stefan D. Loren notified the board he will not stand for reelection as a Class III director at the company’s 2026 annual meeting; his decision was not due to any disagreement with the company.
• The company and Dr. Loren entered a one‑year consulting agreement effective July 8, 2026 under which he will be paid $15,000 per quarter and, at the end of the term, receive a stock option grant for 15,000 shares. Options granted to him (past and future) remain exercisable for 10 years from their grant dates.
• Pursuant to a securities purchase agreement and a related Board Designation Side Letter with Nantahala Capital Management, LLC dated May 4, 2026, Nantahala selected Andrew Gu as its board designee. On May 18, 2026 the board appointed Andrew Gu as a Class III director and named him to the Audit Committee. Mr. Gu is an analyst at Nantahala (since June 2021) and holds degrees in Economics (Finance concentration) and Neuroscience from the University of Pennsylvania.

Key Details

• Dr. Loren notified the board on May 17, 2026; his term expires at the 2026 annual meeting.
• Consulting agreement effective July 8, 2026: $15,000 per quarter for one year; 15,000‑share option grant at term end; options exercisable for 10 years.
• Andrew Gu appointed May 18, 2026 as Class III director and Audit Committee member; selected by Nantahala under a May 4, 2026 investor agreement.
• No family relationships or transactions requiring disclosure under Item 404(a) were reported for Mr. Gu.

Why It Matters

• The filing signals a planned board transition with continued involvement from Dr. Loren in a paid consulting role and an investor‑driven addition to the board.
• Nantahala’s right to designate a director (from the May 4 financing/side letter) has been exercised, which may affect board composition and investor influence going forward.
• Investors should note the governance change (new Audit Committee member) and the modest cash and equity compensation tied to Dr. Loren’s consulting arrangement; these are factual items that could be relevant to oversight and potential dilution from option grants.